New Compass Pathways’ patent?
New patent app published today
Filed Feb 10th under “Track One” it received prioritized examination & was allowed on April 5th
The issue fee was already paid—a granted patent will issue soon
This will become Compass’ 4th US patent
1/4
Conversation
Compass’ first 3 US patents claim psilocybin “Polymorph A”
This one claims psilocybin “Hydrate A”
Polymorph A & Hydrate A are characterized & claimed by different XRPD peaks
A “hydrate” is a crystal form that also contains water molecules
(It’s a different solid form)
2/4
1
1
The examiner allowed Compass’ claims because “the closest prior art of record” states “Nothing indicates polymorphisms”
The application was allowed without a single rejection
Note Compass’ app also discloses Polymorphs A-prime & B
Will these two forms be patented next?
3/4
2
1
Compass’ app: appft.uspto.gov/netacgi/nph-Pa
File history: patentcenter.uspto.gov/#!/application
Follow all Compass patents with the @PsilocybinAlpha Psilocybin Patent Tracker: psilocybinalpha.com/data/psilocybi
4/4
1
5
Graham, how does a patent application receive prioritized examination? just by paying more?
1
1
This Tweet is from a suspended account. Learn more
Indeed, “good news” depends on where you sit—I’d imagine Compass is happy, & their patent lawyers are toasting their success (2 months to issuance is about the fastest I’ve seen). Does it also accelerate patient access? Does psilocybin hydrate A bring other benefits to the world?
1
2
Show replies